Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ: SNGX )

2.110 +0.040 (+1.93%)
Streaming Delayed Price Updated: 10:24 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Via TheNewswire.com
Exposures Product Safety
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Study Shows the Gut is Key in Protecting the Brain After Stroke
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Via Investor Brand Network
Exposures COVID-19
Study Shows Bioengineered Materials Can Treat Oral Mucositis
Via Investor Brand Network
BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Exposures COVID-19
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via TheNewswire.com
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
By Kyle Anthony, Benzinga 
Via TheNewswire.com
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
By Kyle Anthony, Benzinga 
Via TheNewswire.com
Exposures COVID-19
Soligenix Targets Psoriasis With New Therapy
Soligenix Targets Psoriasis With New Therapy 
Via News Direct
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing. 
Via Benzinga
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL 
Via News Direct
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks. 
Via Benzinga
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs 
Via News Direct
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Soligenix Announces Participation at the Spartan Capital Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.